Literature DB >> 11951274

Posttraumatic anosmia in craniofacial trauma.

D F Jimenez1, S Sundrani, C M Barone.   

Abstract

Although the clinical implications of anosmia can be significant, posttraumatic anosmia is generally given relatively little attention in the clinical setting. Patients who sustain craniofacial trauma are most at risk. The incidence of posttraumatic anosmia varies according to the severity of injury and has an overall estimated incidence of 7%. Factors that increase the risk of developing anosmia include anterior skull base fractures, bilateral subfrontal lobe injury, dural lacerations, and cerebrospinal fluid leakage. Recovery of function has been estimated to be approximately 10%. Time of recovery, if it occurs, varies between 8 weeks and 2 years. Presented herein are the clinical, radiographic, pathophysiologic, and anatomic substrata of posttraumatic anosmia.

Entities:  

Mesh:

Year:  1997        PMID: 11951274

Source DB:  PubMed          Journal:  J Craniomaxillofac Trauma        ISSN: 1074-3219


  4 in total

1.  High-dose IgG suppresses local inflammation and facilitates functional recovery after olfactory system injury.

Authors:  Kohei Nishida; Masayoshi Kobayashi; Eisuke Ishigami; Kazuhiko Takeuchi
Journal:  Ann Clin Transl Neurol       Date:  2022-05-19       Impact factor: 5.430

2.  Olfactory nerve recovery following mild and severe injury and the efficacy of dexamethasone treatment.

Authors:  Masayoshi Kobayashi; Richard M Costanzo
Journal:  Chem Senses       Date:  2009-07-03       Impact factor: 3.160

3.  Using the olfactory system as an in vivo model to study traumatic brain injury and repair.

Authors:  Elizabeth Steuer; Michele L Schaefer; Leonardo Belluscio
Journal:  J Neurotrauma       Date:  2014-06-17       Impact factor: 5.269

4.  Anti-high mobility group box 1 antibody suppresses local inflammatory reaction and facilitates olfactory nerve recovery following injury.

Authors:  Masayoshi Kobayashi; Kengo Tamari; Mohammed Omar Al Salihi; Kohei Nishida; Kazuhiko Takeuchi
Journal:  J Neuroinflammation       Date:  2018-04-26       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.